<DOC>
	<DOCNO>NCT01928394</DOCNO>
	<brief_summary>ADDENDUM- PLEASE NOTE : AS OF JANUARY 2017 , THIS STUDY IS ONLY RECRUITING PATEINTS WITH BLADDER AND PANCREATIC CANCER . To investigate safety efficacy Nivolumab single agent combination Ipilimumab 6 tumor type - triple-negative breast cancer ( TNBC ) , gastric cancer ( GC ) , pancreatic adenocarcinoma ( PC ) , small cell lung cancer ( SCLC ) , bladder cancer ( BC ) , ovarian cancer ( OC ) . A combination Nivolumab Ipilimumab Cobimetinib also investigate PC .</brief_summary>
	<brief_title>A Study Nivolumab Itself Nivolumab Combined With Ipilimumab Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>The following Tumor Types close enrollment : Triple Negative Breast Cancer Gastric Cancer Ovarian Cancer Small Cell Lung Cancer</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects histologically confirm locally advanced metastatic disease follow tumor type : Triple Negative Breast Cancer Gastric Cancer Pancreatic Cancer Small Cell Lung Cancer Bladder Cancer Ovarian Cancer Subjects must measurable disease Eastern Cooperative Oncology Group ( ECOG ) 0 1 Adequate hematological organ function confirm laboratory value Active brain metastasis leptomeningeal metastasis Subjects active , know suspected autoimmune disease Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day treatment Prior therapy experimental antitumor vaccine ; T cell costimulation checkpoint pathway , antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , include Ipilimumab ; medicine specifically target T cell also prohibit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>